Contemporary global management of 21-hydroxylase deficiency congenital adrenal hyperplasia in early infancy: a multi-national registry study
Open Access
- 14 January 2026
- journal article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 194 (2) , 123-135
Abstract
Objective: Management of 21-hydroxylase deficiency (21-OHD) congenital adrenal hyperplasia (CAH) in early infancy is challenging, with extent of variation in management unclear. Design and Methods: Using the I-CAH Registry, we retrospectively reviewed management over the first 90 days of life of 154 infants with 21-OHD born in 2018-2023, across 33 centers in 18 countries. Results: Of 154 infants (92 female, 62 male), 136 were diagnosed postnatally, with median (10th centile, 90th centile) presentation age of Day 4 (0, 20.8). At initial hospital discharge, median doses of hydrocortisone (HC), fludrocortisone (FC), and salt were 17 (11.4, 39.6) mg/m2/day, 100 (50, 200) mcg/day and 3.5 (1.6, 8.7) mmol/kg/day, and at Day 90 (D90) 14.5 (8.7, 24.1) mg/m2/day, 100 (50, 200) mcg/day, and 2.1 (1.0, 5.2) mmol/kg/day, respectively. Hyponatremia, hyperkalemia, and hypoglycemia were reported in 70.0%, 71.9%, and 13.0% of infants, respectively. At D90, hyponatremia and hyperkalemia were reported in 7.4% and 28.6%, respectively. At D90, BP measurements were recorded in 30.5%, amongst whom 31.9% had hypertension reported. Median total hospitalization duration over 90 days was 9 days (2, 24). Adrenal crises were associated with 40. 6% of hospitalization episodes. Percentages (males:females) of cases seen by a pediatric endocrinologist, psychologist, pediatric endocrine nurse specialist, and surgeon by D90 were 95.9% (58:84), 33.3% (9:35), 42.1% (20:36), and 23.8% (0:35), respectively. Conclusions: Contemporary management of CAH in early infancy varies considerably. Hypertension and hyperkalemia are frequently reported. Our data may help inform development of quality indicators for benchmarking CAH care in infancy.Keywords
Funding Information
- Diurnal Ltd and research
- Medical Research Council United Kingdom (G1100236)
- seventh framework program
- European Union (201444)
- European Society for Paediatric Endocrinology
This publication has 35 references indexed in Scilit:
- Long-term cardiometabolic morbidity in young adults with classic 21-hydroxylase deficiency congenital adrenal hyperplasiaEndocrine, 2023
- Delivery of multidisciplinary care in the field of differences and disorders of sex development (DSD)Expert Review of Endocrinology & Metabolism, 2022
- Society for Endocrinology UK Guidance on the initial evaluation of a suspected difference or disorder of sex development (Revised 2021)Clinical Endocrinology, 2021
- Clinical Impact and Cost Efficacy of Newborn Screening for Congenital Adrenal HyperplasiaThe Journal of Pediatrics, 2020
- Evaluation of the Dutch neonatal screening for congenital adrenal hyperplasiaArchives of Disease in Childhood, 2019
- Psychological adjustment, quality of life, and self-perceptions of reproductive health in males with congenital adrenal hyperplasia: a systematic reviewEndocrine, 2018
- Parental management of adrenal crisis in children with congenital adrenal hyperplasiaJournal for Specialists in Pediatric Nursing, 2017
- Should we question early feminizing genitoplasty for patients with congenital adrenal hyperplasia and XX karyotype?Journal of Pediatric Surgery, 2016
- Blood pressure, fludrocortisone dose and plasma renin activity in children with classic congenital adrenal hyperplasia due to 21‐hydroxylase deficiency followed from birth to 4 years of ageClinical Endocrinology, 2014
- Congenital adrenal hyperplasia — Pharmacologic interventions from the prenatal phase to adulthoodPharmacology & Therapeutics, 2011